The Foundation Assar Gabrielsson Prize Recipients 2024 Awarded
The Foundation Assar Gabrielsson Prize Recipients 2024 Awarded
GOTHENBURG, Sweden, May 16, 2024 /PRNewswire/ -- Assar Gabrielsson was one of the founders of Volvo. In accordance with his wishes, a fund was established for clinical research of cancer diseases. The fund has existed since 1962. It primarily supports research projects that are considered promising but have not yet reached the weight that provides funding from major research funds.
瑞典哥德堡,2024年5月16日 /PRNewswire/ — 阿萨尔·加布里尔森是沃尔沃的创始人之一。根据他的意愿,设立了一个癌症疾病临床研究基金。该基金自1962年以来一直存在。它主要支持被认为有前景但尚未达到主要研究基金资助的权重的研究项目。
The Assar Gabrielsson Foundation has awarded Anna Wenger as the winner in the basic science research category and Sara Bjursten as the winner in the clinical research category. The prize recipients are rewarded with SEK 100,000 each as extra research grants, administered by the Sahlgrenska Academy at the University of Gothenburg.
阿萨尔·加布里尔森基金会授予安娜·温格为基础科学研究类别的获胜者,萨拉·比尔斯滕为临床研究类别的获胜者。获奖者每人将获得10万瑞典克朗作为额外研究补助金,由哥德堡大学萨尔格伦斯卡学院管理。
"Anna Wenger is awarded the prize in the category of basic science research for advanced basic science studies on malignant gliomas in children and adults. The studies provide new knowledge about epigenetic differences and cancer stem cells different types of glioma. The results can be of great benefit for the development of better diagnostics and choice of treatment for patients with glioma," says Eva Forssell-Aronsson, professor at the University of Gothenburg and executive member of the Assar Gabrielsson Foundation in the citation.
“安娜·温格因对儿童和成人恶性神经胶质瘤的高级基础科学研究而获得基础科学研究类别的奖项。这些研究提供了有关表观遗传学差异和癌症干细胞不同类型的神经胶质瘤的新知识。哥德堡大学教授、阿萨尔·加布里尔森基金会执行成员伊娃·福塞尔-阿隆森在引文中说,这些结果可以为神经胶质瘤患者开发更好的诊断方法和治疗选择。
"Sara Bjursten receives the award in the category of clinical research for clinically important and well-conducted research regarding immunotherapy in cancer patients. The studies provide new knowledge about side effects in the central nervous system, especially with regard to T cells and biomarkers in the blood. The results may lead to new strategies for early detection of side effects in these patients," says Professor Eva Forssell-Aronsson.
“萨拉·比尔斯滕因有关癌症患者免疫疗法的临床重要且进行良好的研究而获得临床研究类别的奖项。这些研究提供了有关中枢神经系统副作用的新知识,尤其是与血液中的T细胞和生物标志物有关的新知识。这些结果可能会为早期发现这些患者的副作用提供新的策略。” 伊娃·福塞尔-阿隆森教授说。
Journalists who want further information, please contact:
想了解更多信息的记者,请联系:
Torbjörn Holmström, Chairman of the Assar Gabrielssons Foundation, 031 66 10 73, or Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation, 070 372 26 26.
阿萨尔·加布里尔森基金会主席托尔布约恩·霍尔姆斯特罗姆,031 66 10 73,或阿萨尔·加布里尔森基金会执行成员伊娃·福塞尔-阿隆森,070 372 26 26。
For more information, please visit volvogroup.com For frequent updates, follow us on X: @volvogroup
欲了解更多信息,请访问 volvogroup.com 如需频繁更新,请在 X 上关注我们: @volvogroup
The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers' uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2023, net sales amounted to SEK 553 billion (EUR 48 billion). Volvo shares are listed on Nasdaq Stockholm.
沃尔沃集团通过运输和基础设施解决方案推动繁荣,提供卡车、公共汽车、建筑设备、船舶和工业应用的动力解决方案、延长客户正常运行时间和生产力的融资和服务。沃尔沃集团成立于1927年,致力于塑造可持续交通和基础设施解决方案的未来格局。沃尔沃集团总部位于瑞典哥德堡,拥有超过10万名员工,为近190个市场的客户提供服务。2023 年,净销售额为 5,530 亿瑞典克朗(480 亿欧元)。沃尔沃股票在斯德哥尔摩纳斯达克上市。
This information was brought to you by Cision
这些信息是由 Cision 带给你的
The following files are available for download:
以下文件可供下载:
Press Release - The Foundation Assar Gabrielsson Prize recipients 2024 awarded | |
AssarGabrielsson 23 |
新闻稿-2024年阿萨尔·加布里尔森基金会奖获得者颁发 | |
AssarGabrielsson 23 |
SOURCE AB Volvo
来源 AB Volvo